Advertisements



Novartis (NVS) Announces Positive Data on Heart Failure Drug

Novartis AG.....»»

Category: topSource: zacksMar 20th, 2017

Novartis (NVS) Announces Positive Data on Heart Failure Drug

Novartis AG.....»»

Category: topSource: zacksMar 20th, 2017

Novartis (NVS) Presents Positive Data on Cardiovascular Drug

Novartis (NVS) presented new analysis from the PARADIGM-HF study on Entresto at a scientific meeting of the Heart Failure Society of America. Novartis AG NVS announces new analysis from the PARADIGM-HF study on its cardiovascular drug, Entresto.....»»

Category: topSource: zacksSep 19th, 2016

Novartis Offers Positive Data on Cardiovascular Drug Entresto

Novartis (NVS) announces new analysis from the PARADIGM-HF study on Entresto at a scientific session of the American Heart Association. Novartis AG NVS announced new analysis of the PARADIGM-HF study on its cardiovascular drug, Entresto, at a s.....»»

Category: topSource: zacksNov 16th, 2016

Novartis Profit Dented by Investment in New Drugs

Novartis said profit fell in the first quarter as it pumped investment into the launch of its new heart-failure drug Entresto that it hopes will help offset revenue lost as best-selling cancer medicine Gleevec loses out to cheaper competitors......»»

Category: smallbizSource: wsjApr 25th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. Roche Holdings AG RHHBY recently announced encouraging results from the phase III study, ALUR on l.....»»

Category: topSource: zacksApr 5th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Zacks.....»»

Category: topSource: redinewsApr 5th, 2017

Novartis" Acute Heart Failure Drug Fails in Late-Stage Study

Novartis AG NVS .....»»

Category: futuresSource: nasdaqMar 22nd, 2017

Novartis" Acute Heart Failure Drug Fails in Late-Stage Study

Novartis AG (NVS) re.....»»

Category: topSource: zacksMar 22nd, 2017

Novartis Offers Positive Data on Breast Cancer Drug LEE011

Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer. Shares of Novartis AG NVS gained 3.2% after the company announced encouraging data from a phase II.....»»

Category: topSource: zacksDec 12th, 2016

Novartis/Amgen Migraine Drug Positive in Phase III Study

Novartis (NVS) and Amgen (AMGN) migraine treatment AMG 334 hit the primary endpoint in the second phase III episodic migraine study. Novartis AG NVS and partner Amgen Inc. AMGN announced positive top-line data from the second pivotal phase III .....»»

Category: topSource: zacksNov 18th, 2016

Boston Scientific (BSX) Reports Positive Data on HeartLogic

Boston Scientific (BSX) recently announced positive data from the first clinical trial on the HeartLogic Heart Failure Diagnostic Service to detect impending heart failure decompensation. Boston Scientific Corporation BSX recently announced po.....»»

Category: topSource: zacksNov 17th, 2016

Novartis Offers Positive Data on Cardiovascular Drug Entresto

Zacks.....»»

Category: topSource: redinewsNov 16th, 2016

Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC. Novartis AG NVS announced positive top-line data from a phase III study (ASCEND-4) on its oncology drug, Zykadia, fo.....»»

Category: topSource: zacksSep 23rd, 2016

Novartis Says MS Drug Cut Risk of Disability Advance in Study

"These data are a positive stride forward," says Novartis CMO. Novartis’s investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company sa.....»»

Category: europeSource: fortuneSep 17th, 2016

Novartis Reports Positive Phase II Data on Migraine Drug

Novartis AG (NVS) announced results from a phase II study on migraine candidate AMG 334. Novartis AG NVS announced results from a phase II study on migraine candidate AMG334.Data from the study were presented at the fifth European Headache and .....»»

Category: topSource: zacksSep 16th, 2016

Novartis (NVS) Reports Positive Data on Ultibro Breezhaler

Novartis Pharma AG (NVS) announced positive results from a head-to-head study, FLAME, on COPD drug Ultibro Breezhaler. Novartis Pharma AG NVS announced positive results from a head-to-head study, FLAME, on Ultibro Breezhaler at the 2016 Europe.....»»

Category: topSource: zacksSep 6th, 2016

Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet. Roche Holding AG RHHBY announced new retrospec.....»»

Category: topSource: zacks12 hr. 12 min. ago

Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data. This week, there were quit.....»»

Category: topSource: zacks13 hr. 27 min. ago

Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study

Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy. .....»»

Category: smallbizSource: nytMay 23rd, 2017

Novartis" (NVS) Lung Cancer Drug Gets Positive CHMP Opinion

Novartis (NVS) rec.....»»

Category: topSource: zacksMay 22nd, 2017